Literature DB >> 22891005

Teicoplanin-induced leucopenia with immediate resolution after administration of G-CSF.

Peysh Patel1, Jonathan Sandoe, Wazir Baig.   

Abstract

Teicoplanin is used in a wide range of clinical settings, owing to its wide antiGram positive bacterial activity. Although it is generally well tolerated, adverse reactions such as fever and rash are well recognised. Haematological sequelae have been rarely reported. This case report describes the development of teicoplanin-induced leucopenia in a patient with infective endocarditis. A short course of lenograstim, a recombinant granulocyte colony-stimulating factor (G-CSF) reverted biochemical abnormalities. To the authors' best knowledge, this is the first documented example of implementation of G-CSF in such a clinical setting.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22891005      PMCID: PMC3433501          DOI: 10.1136/bcr.01.2012.5668

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  Teicoplanin in patients with chronic renal failure on dialysis: microbiological and pharmacokinetic aspects.

Authors:  L O Neville; R Baillod; D Grady; W Brumfitt; J M Hamilton-Miller
Journal:  Int J Clin Pharmacol Res       Date:  1987

Review 2.  Structure and mechanism of action of teicoplanin.

Authors:  F Parenti
Journal:  J Hosp Infect       Date:  1986-03       Impact factor: 3.926

3.  In vitro activity and human pharmacokinetics of teicoplanin.

Authors:  L Verbist; B Tjandramaga; B Hendrickx; A Van Hecken; P Van Melle; R Verbesselt; J Verhaegen; P J De Schepper
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

Review 4.  Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy.

Authors:  Françoise Van Bambeke
Journal:  Curr Opin Investig Drugs       Date:  2006-08

5.  Vancomycin-induced neutropenia resolves after substitution with teicoplanin.

Authors:  S E Sanche; W N Dust; Y M Shevchuk
Journal:  Clin Infect Dis       Date:  2000-09       Impact factor: 9.079

Review 6.  Vancomycin-induced neutropenia: is it dose- or duration-related?

Authors:  Emily Black; Tim T Y Lau; Mary H H Ensom
Journal:  Ann Pharmacother       Date:  2011-04-26       Impact factor: 3.154

7.  The efficacy of teicoplanin in the treatment of endocarditis caused by gram-positive bacteria.

Authors:  E Presterl; W Graninger; A Georgopoulos
Journal:  J Antimicrob Chemother       Date:  1993-05       Impact factor: 5.790

8.  Glycopeptide-induced neutropenia: cross-reactivity between vancomycin and teicoplanin.

Authors:  Shu-Hwa Hsiao; Chia-Ming Chang; Jui-Chen Tsai; Chia-Yin Lin; Li-Hsiang Liao; Wen-Liang Lin; Ta-Jen Wu
Journal:  Ann Pharmacother       Date:  2007-04-10       Impact factor: 3.154

9.  [Leukopenia due to anti-tuberculous chemotherapy including rifampicin and isoniazid].

Authors:  Naohiro Nagayama; Yuichiro Shishido; Kimihiko Masuda; Motoo Baba; Atsuhisa Tamura; Hideaki Nagai; Shinobu Akagawa; Yoshiko Kawabe; Kazuko Machida; Atsuyuki Kurashima; Hikotaro Komatsu; Hideki Yotsumoto
Journal:  Kekkaku       Date:  2004-05

10.  Leukopenia with neutropenia associated with teicoplanin therapy.

Authors:  A Del Favero; L Patoia; G Bucaneve; L Biscarini; F Menichetti
Journal:  DICP       Date:  1989-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.